Lead Product(s) : Emraclidine
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : AbbVie Inc
Deal Size : $8,700.0 million
Deal Type : Acquisition
Details : Through the acquisition, Abbvie expands neuroscience pipeline with multiple clinical-stage and preclinical candidates, including CVL-231 (emraclidine), with potential across several diseases including schizophrenia, Parkinson's disease (PD), and mood dis...
Brand Name : CVL-231
Molecule Type : Small molecule
Upfront Cash : $8,700.0 million
December 06, 2023
Lead Product(s) : Emraclidine
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : AbbVie Inc
Deal Size : $8,700.0 million
Deal Type : Acquisition
Lead Product(s) : Emraclidine
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Emraclidine is a positive allosteric modulator designed to selectively target the M4 muscarinic receptor subtype. Emerging evidence suggests that activation of M4 muscarinic acetylcholine receptor subtypes can reduce striatal dopamine signaling and reduc...
Brand Name : CVL-231
Molecule Type : Small molecule
Upfront Cash : Not Applicable
December 19, 2022
Lead Product(s) : Emraclidine
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Emraclidine
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : CVL-231 (emraclidine), is a positive allosteric modulator designed to selectively target the M4 muscarinic receptor subtype. Emerging evidence suggests that activation of M4 muscarinic acetylcholine receptor subtypes can reduce striatal dopamine signalin...
Brand Name : CVL-231
Molecule Type : Small molecule
Upfront Cash : Not Applicable
December 15, 2022
Lead Product(s) : Emraclidine
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Emraclidine
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : Morgan Stanley & Co
Deal Size : $254.0 million
Deal Type : Public Offering
Details : Cerevel intends to use the net proceeds to accelerate market development and pre-commercial planning activities for emraclidine and tavapadon, to advance the remainder of the programs in its pipeline, including darigabat, and its other promising earlier-...
Brand Name : CVL-231
Molecule Type : Small molecule
Upfront Cash : Undisclosed
August 12, 2022
Lead Product(s) : Emraclidine
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : Morgan Stanley & Co
Deal Size : $254.0 million
Deal Type : Public Offering
Lead Product(s) : Emraclidine
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : Morgan Stanley
Deal Size : $250.0 million
Deal Type : Public Offering
Cerevel Therapeutics Announces Proposed Public Offering of Common Stock
Details : Cerevel intends to use the net proceeds to support the continued development of emraclidine, including to accelerate registration-enabling activities, to evaluate the potential of emraclidine in other populations, including Alzheimer’s disease psychosi...
Brand Name : CVL-231
Molecule Type : Small molecule
Upfront Cash : Undisclosed
August 10, 2022
Lead Product(s) : Emraclidine
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : Morgan Stanley
Deal Size : $250.0 million
Deal Type : Public Offering
LOOKING FOR A SUPPLIER?